Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Ann Arbor, Michigan 48109


We propose to examine several angiogenic/angiostatic mediators in the skin and serum of subjects with SSc and compare it to levels found in the skin and serum of healthy subjects.

Study summary:

Systemic sclerosis (SSc) is a connective tissue disease that is characterized by fibrosis of the skin and internal organs. One of the earliest pathologic changes in patients with SSc is damage to the blood vessels. Many abnormalities have been found in the inner layer of the blood vessel, the enothelial tissue. It is known that there are mediators in the blood and tissues of the body that affect the endothelial tissue. These are called angiogenic (promote blood vessel formation) and angiostatic (inhibit blood vessel formation) mediators. Many of these mediators have been examined in the peripheral blood of patients with SSc, but fewer of these mediators have been examined at the site of action, in the tissue near the microvasculature. We hypothesize that there are differences in the levels of angiogenic/angiostatic mediators between healthy subjects and subjects with SSc. In addition, we propose that there are differences at skin sites that have varying levels of involvement with SSc of these angiogenic/angiostatic factors in subjects with SSc.


Inclusion Criteria: 1. Meet American College of Rheumatology criteria for systemic sclerosis 2. Subjects with systemic sclerosis must have involvement proximal to the knee or elbow, excluding the face 3. Persons with no chronic health conditions Exclusion Criteria: 1. Persons with systemic sclerosis as a result of being exposed to chemicals or drugs that can cause a sceroderma-like illness 2. Persons with autoimmune diseases other than systemic sclerosis 3. Persons treated with cyclophosphamide in the last 8 weeks 4. Persons with active infections, including but not limited to hepatitis C, hepatitis B, and HIV 5. Persons prone to bleeding because they are treated with medications that thin the blood or have a low platelet count



Primary Contact:

Principal Investigator
Kristine Phillips, MD
University of Michigan

Backup Contact:


Location Contact:

Ann Arbor, Michigan 48109
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.